TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...
Healthline

All About Tysabri’s Dosage

Tysabri (natalizumab) is a prescription drug that’s used to manage Crohn’s disease and certain kinds of multiple sclerosis (MS). The drug comes as an intravenous (IV) infusion. It’s usually given ...
Medscape

PML Reported in Patient Receiving Ocrelizumab

Roche is investigating one case of progressive multifocal leukoencephalopathy (PML) in a patient with multiple sclerosis (MS) after treatment with ocrelizumab (Ocrevus). The company said that ...
ascopubs.org

PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic ...

Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL) No ...
Business Insider

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

CE-VST01-JC is an allogeneic, off-the-shelf, T cell therapy targeting the JC virus, the cause of PML, a rare, rapidly progressing, often fatal illness for which there are no approved treatment options ...
FOX8 Cleveland

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal ...

SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today announced the ...
ascopubs.org

Association between rituximab use and progressive multifocal leukoencephalopathy among non-HIV, non-Hodgkin lymphoma Veteran’s Administration patients.

Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Β-cell non-Hodgkin lymphoma (NHL). Mean age in years at death (sd) 65.1 years (6.9) 67.3 years (6.6) Mean ...